Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Employees

Sector

Biotechnology & Medical Research

Calendar

08/08 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
18/25/18	1.120 $	-0.84%	77,896
17/25/17	1.130 $	-0.88%	1,88,433
16/25/16	1.140 $	-0.87%	1,72,280
15/25/15	1.150 $	-1.71%	97,772
14/25/14	1.170 $	+1.18%	1,32,997

Delayed Quote Nasdaq, July 18, 2025 at 10:50 pm IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.130USD

Average target price

8.500USD

Spread / Average Target

+652.21%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq Other stock markets 10:50:36 18/07/2025 pm IST			5-day change	1st Jan Change
1.120 ^USD	-0.84%		-3.10%	-38.09%

01/07	Chemomab Therapeutics, Ltd. Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis At Bsg Live'25	CI
11/06	Chemomab Therapeutics Ltd. Reports Positive Feedback from Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis	CI

Capitalization	2.17Cr 1.86Cr 1.73Cr 1.61Cr 2.97Cr 186.5Cr 3.32Cr 21Cr 7.89Cr 87Cr 8.12Cr 7.95Cr 321.42Cr	P/E ratio 2025 *	-37.7x	P/E ratio 2026 *	-28.3x
Enterprise value	2.17Cr 1.86Cr 1.73Cr 1.61Cr 2.97Cr 186.5Cr 3.32Cr 21Cr 7.89Cr 87Cr 8.12Cr 7.95Cr 321.42Cr	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	79.48%	Yield 2025 *	-	Yield 2026 *	-

Chemomab Therapeutics, Ltd. Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis At Bsg Live'25	01/07	CI
Chemomab Therapeutics Ltd. Reports Positive Feedback from Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis	11/06	CI
Chemomab Therapeutics Says Nebokitug Awarded New Patent Protections in China, Russia	03/06	MT
Oppenheimer Adjusts Chemomab Therapeutics Price Target to $10 From $11, Maintains Outperform Rating	16/05	MT
Chemomab Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	15/05	CI
Chemomab Therapeutics, Ltd. Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025	05/05	CI
Chemomab Therapeutics Reports Positive Data on Liver Disease Treatment	28/04	MT
Chemomab Therapeutics Names David Weiner as Interim Chief Medical Officer	15/04	MT
Chemomab Therapeutics, Ltd. Announces Management Changes	15/04	CI
Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers	27/03	RE
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers	27/03	CI
Chemomab Therapeutics, Ltd. Announces New Scientific Presentation That Further Confirms the Potential of Nebokitug (CM-101) as a Novel Treatment for Systemic Sclerosis	06/03	CI
Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	03/03	CI

Oppenheimer Adjusts Chemomab Therapeutics Price Target to $10 From $11, Maintains Outperform Rating	16/05	MT
Oppenheimer Adjusts Chemomab Therapeutics Price Target to $11 From $13, Maintains Outperform Rating	15/11	MT
Oppenheimer Upgrades Chemomab Therapeutics to Outperform	06/24/06	MT
Roth MKM Starts Chemomab Therapeutics at Buy, $7 Price Target	06/23/06	MT
Oppenheimer Downgrades Chemomab Therapeutics to Perform From Outperform, Removes $7 Price Target	07/23/07	MT

Chemomab Therapeutics Ltd. Share Price

Equities

CMMB

US16385C1045

Biotechnology & Medical Research

Valuation: Chemomab Therapeutics Ltd.

Chart: Chemomab Therapeutics Ltd.

Latest news: Chemomab Therapeutics Ltd.

Last Transcript: Chemomab Therapeutics Ltd.

Analysts' recommendations: Chemomab Therapeutics Ltd.

Press Releases: Chemomab Therapeutics Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Chemomab Therapeutics Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25	30/06	GL
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25	30/06	AQ
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis	11/06	GL
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis	03/06	GL
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis	03/06	AQ

1 day	+1.33%
1 week	-3.10%
Current month	-3.41%
1 month	-8.16%
3 months	-3.41%
6 months	-46.64%
Current year	-38.09%

1 week	1.12	1.22
1 month	1.12	1.25
Current year	0.89	2.46
1 year	0.87	2.55
3 years	0.42	5.35
5 years	0.42	79
10 years	0.42	79

Manager	Title	Age	Since
Adi Mor CEO	Chief Executive Officer	44	01/06/2023
Sigal Fattal DFI	Director of Finance/CFO	54	01/06/2023
David Weiner CTO	Chief Tech/Sci/R&D Officer	60	03/12/2021

Director	Title	Age	Since
Adi Mor BRD	Director/Board Member	44	22/09/2011
Nissim Darvish CHM	Chairman	60	01/06/2023
Alan Moses BRD	Director/Board Member	77	16/03/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CHEMOMAB THERAPEUTICS LTD.	-0.84%	-3.10%	-0.84%	-64.20%	2.17Cr
ARGENX SE	+0.24%	+2.39%	+15.57%	+35.09%	3.48TCr
WUXI APPTEC CO., LTD.	+1.95%	+17.76%	+110.61%	-21.33%	3.23TCr
BIONTECH SE	-0.94%	-2.65%	+27.24%	-31.75%	2.73TCr
SUMMIT THERAPEUTICS INC.	-3.00%	+6.14%	+172.16%	+2,290.63%	2.05TCr
INSMED INCORPORATED	-0.96%	+5.11%	+37.48%	+356.21%	1.98TCr
AKESO, INC.	+0.86%	+29.92%	+251.31%	+518.46%	1.6TCr
WUXI BIOLOGICS (CAYMAN) INC.	+0.88%	+11.09%	+153.10%	-62.43%	1.47TCr
GENMAB A/S	-0.07%	+3.01%	-23.33%	-44.07%	1.36TCr
EXELIXIS, INC.	-1.15%	-1.43%	+96.01%	+105.01%	1.22TCr
Average	-0.07%	+5.57%	+83.93%	+308.16%	1.91TCr
Weighted average by Cap.	-0.11%	+5.50%	+84.97%	+323.05%

	2025 *	2026 *
Net sales	-	-
Net income	-1.45Cr -1.25Cr -1.16Cr -1.08Cr -2Cr -125.23Cr -2.23Cr -14Cr -5.3Cr -59Cr -5.45Cr -5.34Cr -215.82Cr	-2.61Cr -2.24Cr -2.08Cr -1.94Cr -3.58Cr -224.5Cr -3.99Cr -25Cr -9.5Cr -105.26Cr -9.78Cr -9.58Cr -386.91Cr
Net Debt	-	-